Navigation Links
GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma

CHICAGO, June 04, 2007 /PRNewswire/ -- GlaxoSmithKline today announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC), ovarian cancer and soft tissue sarcoma (STS). These trials were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results observed in these trials with pazopanib support further investigations.

Pazopanib is an oral, investigational angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-kit, important proteins in the angiogenic process. Angiogenesis, which is the growth of new blood vessels in the body, plays a critical role in the growth and spread of tumors. (1,2)

Renal cell carcinoma study (Abstract 5031) (3)

This ongoing Phase II randomized discontinuation study is evaluating patients with advanced or metastatic RCC who have not received prior systemic therapy or have failed one prior therapy (cytokine or bevacizumab-containing regimen). All patients received 800 mg of pazopanib taken orally, once-daily during a 12 week lead-in period. Based on data available on 60 patients at the time of a planned interim analysis, the Independent Data Monitoring Committee (IDMC) recommended that randomization to placebo for patients with stable disease should be discontinued. The study continued as an open-label, single- arm study with all patients receiving pazopanib.

The preliminary week 12 response rate for all 225 patients was 27%. In addition, stable disease was achieved in 46% of patients for a total disease control rate of 73%. Responses have been observed beyond week 12, and the overall response rate will be reported at study completion. Response was determined according to RECIST (Response Evaluation Criteria In Solid Tumors) which is a set of published rules that defines when
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:9/18/2014)... YORK , Sept. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced today ... to the position of  Senior Director of Clinical ... Research, Mr. James has established and led successful global ... Europe , to facilitate the clinical development of ...
(Date:9/18/2014)... JOLLA, Calif. , Sept. 18, 2014 /PRNewswire/ ... RGLS ), a biopharmaceutical company leading the discovery ... today it has initiated its ATHENA natural history ... a life-threatening genetic kidney disease with no approved ... the natural decline of renal function markers such ...
(Date:9/18/2014)... and ROCKVILLE, Md. , Sept. 18, ... ), a biotechnology company with fully integrated commercial and ... and oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary focus on China , ...
Breaking Medicine Technology:Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10
... PALM BEACH, Fla., June 16, 2011 In Florida, seven ... Disease Control, this is just a fraction of the 20,000 ... Over the last decade, the number of such deaths has ... Local West Palm Beach news quotes neighbors ...
... China Pharma Holdings, Inc. (NYSE AMEX: CPHI ... pharmaceuticals company in China, today announced that, in view ... of China Pharma, the NYSE Amex has contacted the ... stated that, while its policy generally is not to ...
Cached Medicine Technology:Law Offices of Spicer & Miller Committed to Combating South Florida's "Pill Mills" Demanding Action and Justice Against Doctors Over Prescribing Medical Drugs to the Public 2China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity 2
(Date:9/18/2014)... Rochelle, NY, September 18, 2014An Emergency Room Decision-Support ... hospital admissions among older adults on Medicare. This ... the nearly 33% of avoidable ER visits that ... costs each year. Details of a successful ERDS ... are published in an article in Population ...
(Date:9/18/2014)... It is almost time to park your Hyundai to ... happier kids. The South Florida Hyundai Dealers Association is ... Children’s Hospital 5K Run/Walk. Its title sponsor is Hyundai ... 5K will take place on Saturday August 20th. The ... City Hall located at 405 Biltmore Way. Registration is ...
(Date:9/18/2014)... Clinical trial report, “Edema Global Clinical Trials ... trial scenario. This report provides elemental information and data ... an overview of the trial numbers and their recruitment ... the globe. The databook offers a preliminary coverage of ... of the sponsors and also provides briefing pertaining to ...
(Date:9/18/2014)... September 18, 2014 Good Neighbor ... launch of Good Neighbor Pharmacy University, an online ... that will educate and empower pharmacy owners and ... healthcare industry continues to evolve, Good Neighbor Pharmacy ... deliver resources and tools to help their businesses ...
(Date:9/18/2014)... 18, 2014 CD-adapco, the largest privately ... today announced its new partnership with Ben Ainslie Racing. ... simulation tool, STAR-CCM+® in the design of its racing ... in the 35th America’s Cup taking place in 2017. ... America’s Cup is sustainability, the set of restrictive rules ...
Breaking Medicine News(10 mins):Health News:Decision-support program helps keep seniors out of the emergency room 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Good Neighbor Pharmacy University Keeps Pharmacists Ahead of the Curve 2Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2
... anti-HLA antibody assays both contribute to characterization ... ... immunosuppression, COLUMBIA, Md., June 1 Data developed by Cylex ... the American Transplantation Congress in Toronto, Canada, suggest,that cell-mediated immunity and ...
... also helped with severe fatigue among patients on chemotherapy ... the more common and unpleasant side effects of treatment ... by the ancient Chinese practice of acupuncture. , A ... and pain and shoulder dysfunction after neck dissection in ...
... treatment of choice for advanced, metastatic prostate cancer has ... testosterone the hormone that fuels prostate-cancer growth ... drugs. While such therapy buys time for patients, it ... resistant to the androgen deprivation and continues to grow. ...
... VA Three new studies published in the June ... focus on what role gender plays in the prognosis ... and the success rates of hearing aid implants in ... the wide variety of critical research being undertaken every ...
... pancreatic, kidney cancers, respectively , , SATURDAY, May ... cancer -- which historically carries a grim prognosis ... cancer drug Gemzar was used after surgery, new ... of pancreatic cancer patients are even candidates for ...
... death for female survivors; cardiovascular events for males ... survived Hodgkin lymphoma as children have an increased risk ... disease as adults, according to a new report. ... -- may help drive these increased risks, according to ...
Cached Medicine News:Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 2Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 3Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 2Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 3Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 2Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 3Health News:New research offers insight into oral cancer, chronic pediatric ear infections, and hearing health 2Health News:New Hope for Tough-to-Treat Cancers 2Health News:New Hope for Tough-to-Treat Cancers 3Health News:Hodgkin Lymphoma Kids Face Greater Risk of Future Problems 2
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices....
... ADx pacemaker family, which ... dual-chamber pacemaker, provides clinicians ... including the revolutionary AF ... U.S. commercially approved algorithm ...
... ADx pacemaker family, which includes ... provides clinicians with the most ... the revolutionary AF Suppression™ algorithm, ... commercially approved algorithm designed to ...
Medicine Products: